ArticleFrontiers in oncology2025

A real-world study of palbociclib plus endocrine therapy with or without a short course chemotherapy in the first-line treatment of HR-positive HER2-negative metastatic breast cancer.

Xiangjun Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.